SMS Lifesciences India Limited (SMSLIFE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SMS Lifesciences India Limited (SMSLIFE) has a cash flow conversion efficiency ratio of 0.161x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs340.55 Million ≈ $3.68 Million USD) by net assets (Rs2.12 Billion ≈ $22.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is SMS Lifesciences India Limited worth for the company's overall valuation and market capitalisation.
SMS Lifesciences India Limited - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how SMS Lifesciences India Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SMS Lifesciences India Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SMS Lifesciences India Limited ranked by their cash flow conversion efficiency. Explore cash flow quality index of SMS Lifesciences India Limited to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Omax Autos Limited
NSE:OMAXAUTO
|
0.061x |
|
TechPrecision Corporation Common stock
NASDAQ:TPCS
|
0.023x |
|
Rompetrol Well
RO:PTR
|
0.020x |
|
LORDS CHLORO ALKALI ORD T (BSE)
NSE:LORDSCHLO
|
N/A |
|
Exel Composites Oyj
HE:EXL1V
|
0.102x |
|
Yuyu Pharma
KO:000220
|
0.006x |
|
Mister Spex SE
F:MRX
|
0.007x |
|
CammSys Corp
KQ:050110
|
-0.137x |
Annual Cash Flow Conversion Efficiency for SMS Lifesciences India Limited (2016–2025)
The table below shows the annual cash flow conversion efficiency of SMS Lifesciences India Limited from 2016 to 2025. View today's stock price for SMS Lifesciences India Limited for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs2.12 Billion ≈ $22.93 Million |
Rs298.10 Million ≈ $3.22 Million |
0.141x | +12.00% |
| 2024-03-31 | Rs1.94 Billion ≈ $20.94 Million |
Rs243.06 Million ≈ $2.63 Million |
0.126x | +14010783.13% |
| 2023-03-31 | Rs1.64 Billion ≈ $17.74 Million |
Rs1.47K ≈ $15.89 |
0.000x | +100.00% |
| 2022-03-31 | Rs1.65 Billion ≈ $17.84 Million |
Rs-112.41 Million ≈ $-1.22 Million |
-0.068x | -125.04% |
| 2021-03-31 | Rs1.29 Billion ≈ $13.97 Million |
Rs351.70 Million ≈ $3.80 Million |
0.272x | +116.54% |
| 2020-03-31 | Rs1.16 Billion ≈ $12.52 Million |
Rs145.47 Million ≈ $1.57 Million |
0.126x | -55.44% |
| 2019-03-31 | Rs1.06 Billion ≈ $11.50 Million |
Rs299.93 Million ≈ $3.24 Million |
0.282x | +211.71% |
| 2018-03-31 | Rs884.08 Million ≈ $9.56 Million |
Rs80.00 Million ≈ $865.21K |
0.090x | -63.89% |
| 2017-03-31 | Rs808.34 Million ≈ $8.74 Million |
Rs202.60 Million ≈ $2.19 Million |
0.251x | -11.86% |
| 2016-03-31 | Rs691.28 Million ≈ $7.48 Million |
Rs196.59 Million ≈ $2.13 Million |
0.284x | -- |
About SMS Lifesciences India Limited
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, a… Read more